Latest News and Press Releases

Imbria partners with HCMA to boost FORTITUDE-HCM trial enrollment of ninerafaxstat, a novel therapy for patients with non-obstructive HCM.

Imbria Pharmaceuticals Strengthens Leadership, Appoints Dr. Cheruvu as Board Chair; James Januzzi, MD, as Senior Research Advisor and SAB Chair.

BOSTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company revolutionizing cardiovascular disease treatment by targeting cardiac energy metabolism,...

– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – –...

– Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in cardiometabolic HFpEF – – Findings support further...

BOSTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and...

– Ninerafaxstat was well tolerated and showed no impact on systemic hemodynamics in patients with stable angina and chronic coronary syndrome – – These findings support a direct,...

– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...

– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...

– The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in...